2018 MIPS Performance Period QCDR and Qualified Registry Self-Nomination Period Opens

Published on:

CMS is pleased to announce that the 2018 Quality Payment Program self-nomination period for vendors interested in participating as a Qualified Registry or a Qualified Clinical Data Registry (QCDR) will begin on September 1, 2017 and will close at 5:00 PM (Eastern Time) on November 1, 2017. Please submit your completed self-nomination form prior to the close of the self-nomination period to be considered; late submissions will not be accepted.

Additional resources regarding QCDR/Qualified Registry self-nomination are available here, on cms.gov.

If you have submitted your completed 2018 self-nomination form to CMS prior to the close of the self-nomination period, and your application is ready for review, please notify us by email. Please email QCDRVendorSupport@gdit.com if you have submitted a QCDR self-nomination form for consideration, or RegistryVendorSupport@gdit.com if you have submitted a qualified registry self-nomination form. Please make sure to include your 2018 self-nomination form JIRA ticket number in the subject of your e-mail.

Should you have any questions regarding the self-nomination process for the 2018 performance period, please feel free to reach out to the Quality Payment Program Service Center:

  • Telephone (available Monday-Friday, 8:00 AM-8:00 PM Eastern Time): 1-866-288-8292 or TTY: 1-877-715-6222
  • Email: QPP@cms.hhs.gov

Related Content

Christmas ransomware exposed over 300K patient records to dark web
Private equity-backed cardiology group puts cloud-based technology in hands of its cardiologists
AI helps cardiologists deliver personalized healthcare—but there is still plenty of work to do
Indiana hospitals reduce nuisance alerts by 77% with medication decision support software
Leveraging machine learning to rapidly create clinical AI algorithms
How medication reconciliation data consolidation in the EHR enables better patient care

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.